5 results about "Evans Blue" patented technology

The present invention discloses a method for treating thyroid cancer using a radiolabeled cleavage-type Evans Blue degenerated fibroblast-activating protein inhibitor, said drug having excellent safety and tolerance in patients with thyroid cancer and having a very excellent therapeutic prospect in the treatment of thyroid cancer.

This invention provides a detection model for allergic reactions to Qingkailing injection. The model comprises seven modules: a mouse ear blue staining area percentage testing and data storage module; a mouse ear blue staining area scoring module; a mouse ear blue staining area result judgment module; a mouse ear tissue Evans blue (EB) exudate quantitative testing and data storage module; a mouse ear tissue Evans blue exudate calculation module; a mouse ear tissue Evans blue exudate result judgment module; and a result output module. The model provides clear evaluation and analysis methods and result judgment criteria, exhibiting a high detection reaction rate. At a dosage of 10 ml / kg, the reaction rate of Qingkailing injection reaches 100%, and the EB exudate amount is 6-10 times that of the negative control group. Furthermore, the method is simple to operate, less time-consuming, and has good repeatability, accurately and truthfully reflecting whether Qingkailing injection causes allergic reactions. This model has significant value and importance for the quality control, process research, and clinical application safety of Qingkailing injection.

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

This invention discloses an Evans blue-modified nucleic acid aptamer targeting EpCAM, its preparation method, and its application. The Evans blue-modified nucleic acid aptamer EB-SYL3C is composed of SYL3C, a bifunctional chelating agent, and truncated Evans blue. Using EB-SYL3C as a ligand can prolong the blood circulation half-life of SYL3C, as well as improve tumor uptake and tumor retention time, thereby enabling its application in EpCAM-targeted radionuclide diagnosis or treatment.

The present application relates to a radiopharmaceutical aqueous solution and a use thereof. The radiopharmaceutical aqueous solution comprises a complex formed by a targeting molecule modified by an Evans blue (EB) fragment and a radioactive metal nuclide, as well as a stabilizer, the stabilizer preferably being one or two or more among gentisic acid, ethanol, and methionine.